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Abstract: Background: The carbohydrate antigen Sda and its biosynthetic enzyme B4GALNT2 are
highly expressed in normal colonic mucosa but are down-regulated to a variable degree in colon
cancer tissues. Here, we investigated the clinical and biological importance of B4GALNT2 in colon
cancer. Methods: Correlations of B4GALNT2 mRNA with clinical data were obtained from The
Cancer Genome Atlas (TCGA) database; the phenotypic and transcriptomic changes induced by
B4GALNT2 were studied in LS174T cells transfected with B4GALNT2 cDNA. Results: TCGA data
indicate that patients with high B4GALNT2 expression in cancer tissues display longer survival than
non-expressers. In LS174T cells, expression of B4GALNT2 did not affect the ability to heal a scratch
wound or to form colonies in standard growth conditions but markedly reduced the growth in soft
agar, the tridimensional (3D) growth as spheroids, and the number of cancer stem cells, indicating
a specific effect of B4GALNT2 on the growth in poor adherence and stemness. On the transcriptome,
B4GALNT2 induced the down-regulation of the stemness-associated gene SOX2 and modulated gene
expression towards an attenuation of the cancer phenotype. Conclusions: The level of B4GALNT2
can be proposed as a marker to identify higher- and lower-risk colorectal cancer patients.
Keywords: glycosylation; sugar antigens; glycosyltransferases; gene expression; stemness;
microarray analysis
1. Introduction
Colorectal cancer (CRC) remains a worldwide leading cause of cancer deaths, notwithstanding
the improved efficacy of the available therapies. Key factors for the success of the therapy include
an early diagnosis and approaches tailored to the risk profile of each patient, sparing invasive
and expensive therapies to lower-risk patients. Glycosylation is a very frequent post-translational
modification of proteins, which undergoes profound changes during neoplastic transformation [1,2].
The Sda carbohydrate antigen is composed of an α2,3-sialylated galactose residue to which
an N-acetylgalactosamine residue isβ1,4 linked (Siaα2,3(GalNAcβ1,4) Gal-R), where R is the underlying
carbohydrate structure (Figure 1A). The last step of the Sda antigen biosynthesis is mediated by the
enzyme β1,4N-acetylgalactosaminyltransferase 2 (B4GALNT2) [3], the product of the B4GALNT2
gene [4–6]. Transcription of the B4GALNT2 gene generates at least two different transcripts that
only differ in the first exon. These two transcripts contain a translational start site, from which two
different transmembrane polypeptides originate: one, referred to as “long form”, contains an unusually
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long cytoplasmic tail [5,6]; the second, known as “short form”, is provided with a cytoplasmic tail
of conventional length [7]. Previous studies have shown a higher enzymatic activity of the short
form compared with the long form [8]. The normal human colonic mucosa usually expresses very
high levels of the B4GALNT2 mRNA and enzyme activity as well as high levels of the Sda antigen.
On the contrary, in CRC tissues, both the B4GALNT2 [9,10] and the Sda antigen [8] are markedly
down-regulated, although at a very variable level among patients. In fact, in the cancer tissues of
the majority of the patients, B4GALNT2 is virtually undetectable, while in a minority, a quite high
activity is detectable. Both normal and cancerous colonic tissues express mainly, if not exclusively,
the short form of B4GALNT2. The α2,3 sialylated type 2 sugar chains on which B4GALNT2 elaborates
the Sda antigen can also be utilized by fucosyltransferases (mainly fucosyltransferase 6 (FUT6)) for
the biosynthesis of the cancer-associated antigen sialyl Lewis X (sLex) [11–13]. Our group [8] and
others [14] showed that the forced expression of B4GALNT2 in CRC cell lines partially replaces the
sLex with the Sda antigen. In gastrointestinal cell lines, this modification has been shown to reduce
the metastatic potential [14,15]. However, the clinical implications of B4GALNT2 expression in CRC
have never been investigated. To obtain significant clinical correlations between gene expression
and clinical parameters, it is necessary to access large cohorts of fully characterized patients, such as
The Cancer Genome Atlas (TCGA), which contains gene expression and clinical data from hundreds
of patients. Owing to the well-recognized importance of glycosylation in cancer, we used TCGA
data to compare the prognostic predictive potential of several glycosyltransferases involved in the
biosynthesis of cancer-associated glycans. In a preliminary survey of TCGA, we noticed that among
various glycosyltransferases involved in colon cancer, B4GALNT2 displayed a very good predictive
potential in that patients retaining higher levels of B4GALNT2 mRNA displayed a much longer overall
survival. In particular, all long-time survivals displayed high levels of B4GALNT2 mRNA. To obtain
insight into the mechanisms linking B4GALNT2/Sda expression to the CRC phenotype, we analyzed
the phenotype and the transcriptome of LS174T cells transfected with the short form of B4GALNT2.
We found that B4GALNT2 expression reduces the clonogenic ability in non-adherent conditions and
the stemness of the cells through the modulation of the gene expression.
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Figure 1. Biochemical characterization of B4GALNT2-transfected cell lines. (A) the Sda and the sLex
antigens derive from alternative and mutually exclusive terminations of a common α2,3-sialylated
type 2 structure. (B) both the enzymatic activity (dark gray) and the mRNA (light gray) of B4GALNT2
were negligible in Neo cells, but strongly expressed in clones S2 and S11 as detected by RT-PCR and
normalized with β-actin. (C) Western blot analysis of Neo cells and of B4GALNT2-transfected clones
with anti-Sda (left) and anti-sLex (right) antibodies, revealing a partial replacement of the sLex antigen
with the Sda (arrow).
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2. Materials and Methods.
2.1. Analysis of TCGA Database
Gene expression data and clinical information for 623 colorectal adenocarcinoma samples and 51
normal colonic tissues were downloaded from the TCGA database using the Firebrowse website [16].
RNA-Seq by Expectation Maximization (RSEM)-normalized data for the colon adenocarcinoma
(COADREAD) cohort were matched with clinical data from the Clinical Pick Tier1 archive. B4GALNT2
mRNA expression was compared with stage, microsatellite stability (MS) status, response to treatment,
histological type, and survival. Since the samples did not present a normal distribution of B4GALNT2
expression, non-parametric statistical tests were used. The Mann–Whitney test was used to analyze
the difference of B4GALNT2 expression in normal and tumor tissues of mucinous vs. non-mucinous
histological type. The Kruskal–Wallis test was used to evaluate B4GALNT2 mRNA expression across
cancer stages and MSS/MSI groups. The survival curve was estimated by the Kaplan–Meier method,
and the Mantel–Cox log-rank test was performed to test differences between the survival curves.
Identification of highly expressed genes in the high and low B4GALNT2 expressers was performed
through two-way ANOVA and Bonferroni’s multiple comparison test.
2.2. Cell Lines
LS174T(ATCCR® Number: CL-188™) cell line was transfected with an expression vector for the
short form of B4GALNT2 cDNA cloned in pcDNA3 or with the empty vector as detailed previously
[8], generating the two B4GALNT2-expressing clones S2 and S11 and the polyclonal negative control
Neo population, respectively. Cells were cultured in DMEM supplemented with 10% FBS and
antibiotics in a humidified incubator with a 5% CO2 atmosphere at 37 ◦C. B4GALNT2 enzymatic
activity was measured as the difference between the incorporation of radioactive GalNAc on fetuin
and asialofetuin, as previously described [5]. B4GALNT2 mRNA was measured by real-time (RT) PCR
as previously described [17]. Western blot analysis with an anti-Sda antibody KM694 and an anti-sLex
antibody (CSLEX1) was performed as detailed elsewhere [8]. Cell lines were genotyped using highly
polymorphic short tandem repeat loci, which were amplified using the PowerPlex® 16 HS System
(Promega). Fragment analysis was done on an ABI3730xl (Life Technologies), and the resulting data
were analyzed with GeneMarker HID software (Softgenetics) by Microsynth (Switzerland). Reports
are available on request.
2.3. Soft Agar Growth Assay
One milliliter of a 0.5% agar solution in complete DMEM was dispensed in each well of a six-well
plate and allowed to solidify. On top of this layer of agar, 1 mL of a 0.3% agar solution in complete
DMEM medium containing 1 × 104 cells per well was dispensed in triplicate. The plates were incubated
for two weeks at 37 ◦C in a humidified incubator. To evaluate the number of colonies formed, the plates
were fixed and colored for one hour at room temperature with a solution containing formaldehyde (4%)
and crystal violet (0.005%) in phosphate buffered saline (PBS, 20 mM phosphate buffer pH 7.5, 0.15 mM
NaCl). Pictures were taken at 4X magnification, and colonies were counted. Statistical analysis was
performed using the non-parametric Kolmogorov–Smirnov test.
2.4. Tridimensional (3D) Culture
Cells were seeded in six-well plates whose bottoms were coated with 0.5% agar in complete
DMEM. Spheroid growth was monitored every 2–3 days. Owing to their non-adherent condition,
it was impossible to quantitate spheroids by counting. Thus, cells were quantitatively collected and
homogenized, and the protein concentration, as well as the volume of each homogenate, was measured.
The number of cells was calculated using the protein concentration of a homogenate obtained from
a known number of cells grown in standard conditions as a reference.
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2.5. Wound-Healing Assay
The wound-healing assay was performed using Culture-Insert 2 Well (Ibidi). Aliquots of
5 × 104 cells were seeded in each well. When the cells reached confluency, the insert was removed
and the healing of the wound was measured by taking pictures at 4×magnification. The area free of
cells was measured using the MRI Wound Healing Tool of ImageJ [18]. The statistical analysis was
performed using two-way ANOVA and Tukey’s multiple comparisons test.
2.6. ALDEFLUOR Assay
ALDEFLUOR (Stem Cell Technologies) was activated following the manufacturer’s instructions
and added to 5 × 105 aliquots of cells. Half of the cell suspension was treated with DEAB, a specific
ALDH inhibitor used as a negative control. After 45 min at 37 ◦C, cells were washed and suspended in
ALDEFLUOR buffer. The fluorescent signal was acquired with a FACSCalibur flow cytometer and Cell
Quest Pro software. On a dot plot with FL1 (green fluorescence) on the X axis and side scatter (SSC)
on the Y axis, we set the fluorescence of the DEAB sample (negative control) and defined the area for
ALDH-positive cells. Cells included in this area were considered ALDEFLUOR-positive.
2.7. Transcriptomic Analysis
Transcriptomic analysis of RNA from LS174T Neo and S2/S11 cells grown either in standard 2D
conditions or in 3D conditions (as spheroids) was performed in duplicate using Agilent whole human
genome oligo microarray (G4851A) as previously described [19]. Statistical analysis was performed
using a moderated t-test, and the false discovery rate was controlled with the multiple testing correction
Benjamini–Hochberg with Q = 0.05. Pathway analysis of differentially expressed genes was determined
using the web-based software MetaCore (GeneGo, Thomson Reuters). Gene function was studied
through an extensive literature search.
3. Results
3.1. Survey of the TCGA Database
The relationship between B4GALNT2 gene expression and clinical parameters of CRC and normal
specimens was investigated in the transcriptomic data from the TCGA database. As shown in
Figure 2A, the mean level of B4GALNT2 mRNA in CRC tissues was much lower than in normal tissues,
albeit extremely variable. No significant association existed between B4GALNT2 expression and stage
or microsatellite stability status (Figure 2B,C). However, B4GALNT2 expression was significantly higher
in the groups of therapy responder (Figure 2D), non-mucinous subtype (Figure 2E), and wild-type
TP53 (Figure 2F). On the other hand, little or no relationship was observed with KRAS, BRAF, and APC
mutations (data not shown). The most striking effect of the level of B4GALNT2 expression was
observed on the overall survival (Figure 2G). Patients falling in the lower 15th percentile (all lacking
detectable B4GALNT2 mRNA) and those falling in the higher 15th percentile displayed very similar
survival curves within the first 1000 days, while long-term survivals belonged exclusively to the
high-B4GALNT2-expressers group (Figure 2G).
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Figure 2. The Cancer Genome Atlas (TCGA) data. (A) Expression level of B4GALNT2 mRNA in 
normal mucosa and colorectal cancer (CRC) specimens. (B–F) Expression of B4GALNT2 mRNA in 
CRC specimens grouped according to stage (B), microsatellite stability status (C), response to therapy 
(D) subtypes (E), and TP53 mutation (F). (G) Kaplan–Meier survival curves of patients grouped in the 
groups of high expressers (15th upper percentile, red) or no expressers (15th lower percentile, blu) of 
mRNA B4GALNT2 expression. MSS: microsatellite stable; MSI-l: microsatellite instable-low; MSI-h: 
microsatellite instable-high. 
The cohorts of high and low B4GALNT2 expressers displayed very different gene expression 
signatures. In fact, samples from the upper percentile showed up-regulation of several genes (Table 
1), five of which (CLCA1, FCGBP, MUC2, MUC5B, AGR2) were related to the formation of the mucous 
layer. Three genes were involved in the immune function (LCN2, IGJ, PIGR), particularly in the 
formation and transport of polymeric immunoglobulins, while three genes (REG1A, REG4, TFF3) 
were involved in repair and maintenance of the epithelial layer. On the contrary, the growth-
promoting gene IGF2 displayed up-regulation in low B4GALNT2 expressers. Altogether, these data 
support a view in which high B4GALNT2 expressers displayed up-regulation of genes involved in 
functions associated with a normal epithelium (mucus formation, immunoglobulin secretion, and 
epithelial integrity), while low B4GALNT2 expressers were associated with the overexpression of a 
growth-promoting gene. 
Table 1. Genes modulated in high/low B4GALNT2 cohorts. 
Genes Up-Regulated in High B4GALNT2 Expressers 
Gene 
Name 
Protein Functional Class Functions 
p-
Value 
CLCA1 
Chloride Channel 
Accessory 1 
Mucin-related 
Involved in chloride conductance 
and regulation of mucus 
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Figure 2. The Cancer Genome Atlas (TCGA) data. (A) Expression level of B4GALNT2 mRNA in
normal mucosa and colorectal cancer (CRC) specimens. (B–F) Expression of B4GALNT2 mRNA in
CRC specimens grouped according to stage (B), microsatellite stability status (C), response to therapy
(D) subtypes (E), and TP53 mutation (F). (G) Kaplan–Meier survival curves of patients grouped in the
gro ps of high expressers (15th upper percentile, red) or no expressers (15th lower percentile, blu) of
mRNA B4GALNT2 expression. MSS: microsatellite stable; MSI-l: microsatellite instable-low; MSI-h:
microsatellit instable-high. * p ≤ 0.05; **** p ≤ 0.0001.
The cohorts of high and low B4GALNT2 expressers dis lay d very different gen expression
signatures. In fact, samples from the upper perc ntile showed up-regulation of several genes (Table 1),
five of which (CLCA1, FCGBP, MUC2, MUC5B, AGR2) were related to the formation of the mucous layer.
Three genes were involved in the immune function (LCN2, IGJ, PIGR), particularly in the formation
and transp rt of p lymeric immunoglobulins, while thr e genes (REG1A, REG4, TFF3) w r involved
in repair and m intenanc of the epithelial layer. On the contrary, the growth-promotin g ne IGF2
displayed up-regulation in low B4GALNT2 expressers. Altogether, these data support a view in which
high B4GALNT2 expressers displayed up-regulation of genes involved in functions associated with
a normal epithelium (mucus formation, i unoglobulin secretion, and epithelial integrity), while low
B4GALNT2 expressers were associated with the over xpression of a growt -promoting gene.
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Table 1. Genes modulated in high/low B4GALNT2 cohorts.
Genes Up-Regulated in High B4GALNT2 Expressers
Gene
Name Protein
Functional
Class Functions p-Value
CLCA1 Chloride ChannelAccessory 1
Mucin-related
Involved in chloride conductance and
regulation of mucus production. Potential
tumor suppressor. Induces MUC5AC.
****
FCGBP Fc Fragment of IgGBinding Protein
May be involved in the maintenance of the
mucosal structure as a gel-like component of
the mucosa.
****
MUC2 Mucin 2, OligomericMucus/Gel-Forming
Coats the epithelia of the intestines and other
mucous membranes. Downreguled in
inflammatory bowel diseases.
****
AGR2
Anterior Gradient 2,
Protein Disulphide
Isomerase Family Member
Required for MUC2 post-transcriptional
synthesis and secretion. Proto-oncogene. ****
MUC5B Mucin 5B, OligomericMucus/Gel-Forming Coats the epithelia of the mucous membranes. **
LCN2 Lipocalin 2
Immune
function
Limits bacterial growth by sequestering
iron-containing siderophores. *
IGJ Joining Chain OfMultimeric IgA And IgM Joins IgM and IgA in multimeric complexeses. ****
PIGR Poly-immunoglobulinreceptor
Allows the trans-epithelial transport of
polymeric IgA to the gut lumen. ****
REG1A Regenerating familymember 1α
Regeneration
and repair
Regenerating proteins are acute phase reactants,
lectins, antiapoptotic or growth factors.
****
REG4 Regenerating familymember 4 ****
TFF3 Trefoil factor 3
Involved in maintenance and repair of the
intestinal mucosa. Promotes the mobility of
epithelial cells in healing processes.
****
SERPINA1 Serpin family A member 1
Protease
inhibition
Serine protease inhibitor for elastase, plasmin,
thrombin, trypsin, chymotrypsin,
and plasminogen activator.
***
SPINK4 Serine Peptidase InhibitorKazal Type 4 Serine-type endopeptidase inhibitor activity. *
ITM2C Integral MembraneProtein 2C Secretase inhibitor. **
LGALS4 Galectin 4 Binding ofglycoconjugates
Expression restricted to small intestine, colon,
and rectum, and it is down-regulated in
colorectal cancer.
****
Genes Up-Regulated in Low B4GALNT2 Expressers
IGF2 Insulin Like GrowthFactor 2 Growth factor Growth-promoting activity. ****
Genes showing a percentage change (PC) higher than 50 were identified according to the formula: PC = (Mean
15% high −Mean 15% low)/Mean All x 100. Bonferroni’s multiple comparisons test was used for the comparison
between the two cohorts. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
3.2. Phenotypic Impact of B4GALNT2 Expression on Colon Cancer Cells
Owing to the clear association between high B4GALNT2 and better prognosis, the impact of
B4GALNT2 expression on the malignant phenotype of a colon cancer cell line was studied using,
as a model, LS174T cells transfected with the short form of B4GALNT2 or mock-transfected [8].
The three cell lines analyzed were Neo—a polyclonal population of mock-transfectants—and S2 and
S11, two B4GALNT2-transfected clones. As shown in Figure 1B, the level of B4GALNT2 mRNA
and enzyme activity in mock transfectants was nearly undetectable, while it was high in S2 and
S11 clones. In S2 and S11 clones, but not in Neo cells, the Sda antigen was strongly expressed
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on high-molecular-weight proteins. On the other hand, the sLex antigen, which is also carried by
high-molecular-weight proteins, was more strongly expressed by Neo cells than by S2 and S11 clones
(Figure 1C). This is due to the previously documented competition between the fucosyltransferases
synthesizing sLex and B4GALNT2 [8,14] (Figure 1A).
Compared with mock-transfected Neo cells, both S2 and S11 clones displayed a strongly reduced
ability to grow in a semi-solid medium (soft agar) (Figure 3A), forming 20–40% of the clones formed
by Neo cells.
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Figure 3. Phenotypic characterization of B4GALNT2-expressing cells and mock-transfectants.
(A) growth in 0.33% agar. (B) tridimensional growth as spheroids. (C) clone formation in standard
growth conditions. (D) wound healing assay. Experimental details are provided in Materials and
Methods. ** p ≤ 0.01, *** p ≤ 0.001, N.S. = Not significant.
B4GALNT2-expressing clones also displayed a 60% reduction in ability to grow as spheroids
in a completely liquid medium (Figure 3B). Interestingly, the decreased clonogenic capability was
evident only in conditions of poor or no adhesion. Indeed, when a small number of Neo, S2, or S11
cells were seeded in standard conditions, the number of growing colonies was similar (Figure 3C).
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Lastly, the capacity to heal a scratch wound was not significantly affected by B4GALNT2 expression
clones (Figure 3D).
3.3. B4GALNT2 Expression Reduces the Number of Cancer Stem Cells
To investigate the relationship between B4GALNT2 expression and stemness, we analyzed the
three cell lines for the expression of aldehyde dehydrogenase (ALDH), reported to be a stem-cell and
cancer-initiating cell marker in many tissues, including colon tissue [20].
In a typical experiment (Figure 4), cells were incubated with the ALDH substrate ALDEFLUOR,
either in the presence or in the absence of DEAB (a specific ALDH inhibitor) to provide a negative
control. While the percentage of ALDH-positive cells in LS174T Neo was about 40%, it was around
30% in the two B4GALNT2 clones, consistent with a marked reduction in the number of cancer stem
cells (CSC).
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Figure 4. ALDEFLUOR analysis. Cells were incubated with ALDEFLUOR either in the presence or in 
the absence of the inhibitor DEAB. Gates excluding all of the cells labelled in the presence of DEAB 
were set. Cells included in the gate in the absence of DEAB were considered to be ALDH-positive. 
Histograms report the percentage of ALDH-positive cells ± SD in three independent experiments. * p 
≤ 0.05, ** p ≤ 0.01. 
3.4. Impact of B4GALNT2 Expression on the Transcriptome of Colon Cancer Cells 
Figure 4. ALDEFLUOR analysis. Cells were incubated with ALDEFLUOR either in the presence or in
the absence of the inhibitor DEAB. Gates excluding all of the cells labelled in the presence of DEAB
were set. Cells included in the gate in the absence of DEAB were considered to be ALDH-positive.
Histograms report the percentage of ALDH-positive cells ± SD in three independent experiments.
* p ≤ 0.05, ** p ≤ 0.01.
3.4. Impact of B4GALNT2 Expression on the Transcriptome of Colon Cancer Cells
To understand the origin of the dramatic effect of B4GALNT2 on the phenotype of LS174T cells
and, in particular, on the ability to grow in non-adherent conditions, the impact of B4GALNT2 and of
3D growth in liquid medium on the transcriptome of LS174T cells was investigated by microarray
analysis. Using this technology, the mean level of B4GALNT2 expression was found to be three in
Neo and 230 in S2/S11 cells. The heat map graph displayed in Figure 5A reports the modulation
of 142 genes showing a fold change ≥ 2 in LS174T S2 and S11, compared with Neo cells, grown in
standard conditions.
Cells 2020, 9, 948 9 of 18
Cells 2020, 9, 948 9 of 22 
 
To understand the origin of the dramatic effect of B4GALNT2 on the phenotype of LS174T cells 
and, in particular, on the ability to grow in non-adherent conditions, the impact of B4GALNT2 and 
of 3D growth in liquid medium on the transcriptome of LS174T cells was investigated by microarray 
analysis. Using this technology, the mean level of B4GALNT2 expression was found to be three in 
Neo and 230 in S2/S11 cells. The heat map graph displayed in Figure 5A reports the modulation of 
142 genes showing a fold change ≥ 2 in LS174T S2 and S11, compared with Neo cells, grown in 
standard conditions. 
Neo
S11
S2
A
Neo 2D
Neo 3D
B4GALNT2 2D
B4GALNT2 3D
B
 
Figure 5. Heatmaps of gene expression analysis. (A) B4GALNT2-expressing and control Neo LS174T 
cells grown in standard 2D conditions. (B) Cells grown in 3D conditions or in standard 2D conditions. 
High and low expression was normalized to the average expression across all samples. Differences 
were analyzed by the moderated t-test. Corrected p-value cut-off: 0.15; multiple test correction used: 
Benjamini–Hochberg. 
Table 2 shows a synthesis of pathway analysis, indicating that stemness, intracellular signaling, 
and cell adhesion were among the significantly affected pathways. 
Table 2. Pathways modulated by B4GALNT2 expression. 
Pathway Map Network Objects 
Stem cell pathways SOX2, FGFR3, HEY2, IGF1, c-Kit, MEF2C, MLRC, MyHc 
Blood coagulation MyHC, Coagulation factor V, PAR1 
Main growth factor signaling cascades FGFR3, IGF-1 
Chemoresistance pathways c-Kit, IGF-1 
Cell adhesion Nidogen, IGF-1, MyHC, MRLC 
Cytoskeleton remodeling MyHC, MRLC 
G protein-coupled receptors signaling Gα(i)-specific peptide GPCRs, Gα(q)-specific peptide GPCRs 
The analysis of differentially expressed genes was determined using the web-based software 
MetaCore from GeneGo (Thomson Reuters). Original analysis data are reported in Table S1. 
A more in-depth analysis focused on the 25 genes modulated by B4GALNT2 by a fold change ≥ 
4 (Table 3), revealed that four genes displayed up-regulation (above the red line) and 21 displayed 
down-regulation (below the red line).
Figure 5. Heatmaps of gene expression analysis. (A) B4GALNT2-expressing and control Neo LS174T
cells grown in standard 2D conditions. (B) Cells grown in 3D conditions or in standard 2D conditions.
High and low expression was normalized to the average expression across all samples. Differences
were analyzed by the moderated t-test. Corrected p-value cut-off: 0.15; multiple test correction
used: Benjamini–Hochberg.
Table 2 shows a synthesis of pathway analysis, indicating that stemness, intracellular signaling,
and cell adhesion were among the significantly affected pathways.
Table 2. Pathways modulated by B4GALNT2 expression.
Pathway Map Network Objects
Stem cell pathway SOX2, FGFR3, HEY2, IGF1, c-Kit, MEF2C, MLRC, MyHc
Blood coagulation MyHC, Coagulation factor V, PAR1
Main growth factor signaling cascades FGFR3, IGF-1
Chemoresistance pathways c-Kit, IGF-1
Cell adhesion Nidogen, IGF-1, MyHC, MRLC
Cytoskeleton remodeling MyHC, MRLC
G protein-coupled receptors signaling Gα(i)-specific peptide GPC s Gα(q)-specific peptide GPCRs
The analysis of differentially expressed genes was determined using the web-based software MetaCore from GeneGo
(Thomson Reuters). Original analysis data are reported in Table S1.
A more in-depth analysis focused on the 25 genes modulated by B4GALNT2 by a fold change ≥
4 (Table 3), revealed that four genes displayed up-regulation (above the red line) and 21 displayed
down-regulation (below the red line).
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Table 3. Genes highly modulated by B4GALNT2 in LS174T cells.
Gene Symbol
Expression Fold Change
S2/S11 Vs. Neo
p-Value S2/S11
Vs. Neo Gene Name Function in Cancer PMIDNeo S2/S11
CD200 2 27.0 16.8 0.0411 CD200 molecule Possible colon cancer stem cell marker 27574016
NGFRAP1 39 456.3 11.6 0.0383 Nerve growth factor receptor (TNFRSF16)associated protein 1 Overexpression inhibits growth of breast tumor xenografts. 26408910
SKAP1 138 912.3 6.6 0.0231 Src kinase associated phosphoprotein 1 Modulates TCR signaling. 18320039
SLC14A1 2 10.8 5.2 0.0360 Solute carrier family 14 (urea transporter),member 1 (Kidd blood group) Potential tumor suppressor in lung cancer 22223368
FAM26F 8 2.0 −4.1 0.0195 Family with sequence similarity 26, member F Little or no information
FAM110B 9 2.1 −4.5 0.0142 Family with sequence similarity 110, member B Promotes growth of prostate cancer cells 21919029
ALX1 12 2.6 −4.6 0.0167 ALX homeobox 1 Promotes EMT and invasion in ovarian and lung cancer. 2672239723288509
F5 12 2.6 −4.7 0.0331 Coagulation factor V (proaccelerin, labile factor) Little or no information
INMT 9 1.8 −4.7 0.0142 Indolethylamine N-methyltransferase Negatively associated with prostate cancer progression 22075945
MYH3 1198 238.9 −5.0 0.0167 Myosin, heavy chain 3, skeletal muscle,embryonic Little or no information
MBOAT2 14 2.5 −5.4 0.0383 Membrane bound O-acyltransferase domaincontaining 2 Little or no information
ROR1 12 1.8 −6.4 0.0163 Receptor tyrosine kinase-like orphan receptor 1 Associated with ovarian cancer stem cells 25411317
RAI14 51 7.7 −6.6 0.0190 Retinoic acid induced 14 Overexpressed in gastric cancer, associated with worse prognosis. 29654694
FMO3 14 1.8 −7.7 0.0253 Flavin containing monooxygenase 3 Involved in de-toxification of drugs. 16800822
PEG10 44 5.3 −8.4 0.0233 Paternally expressed 10 Enhances cell invasion by upregulating β-catenin, MMP-2 and MMP-9 25199998
NINL 244 28.4 −8.6 0.0339 Ninein-like High expression associates with poor prognosis in prostate cancer 30637711
ARMC4 15 1.7 −8.7 0.0196 Armadillo repeat containing 4 Can be mutated in gastric cancer. 26330360
MID2 32 2.1 −15.0 0.0152 Midline 2 In breast cancer associates with BRCA1 and promotes growth. 26791755
SOX2 28 1.7 −16.5 0.0163 SRY (sex determining region Y)-box 2 Associated with motility and a cancer stem cell phenotype in CRC 2922871630518951
LGALS2 362 21.5 −16.8 0.0142 Lectin, galactoside-binding, soluble, 2 Elevated in plasma of CRC patients. Promotes adhesion to endothelia. 21933892
NPTX1 42 2.4 −17.3 0.0123 Neuronal pentraxin I Anti proliferative in colon cancer 29345391
GALC 49 2.0 −24.9 0.0077 Galactosylceramidase Unclear
STARD3NL 98 3.6 −27.4 0.0346 STARD3 N-terminal like Little or no information
ZNF22 83 1.9 −44.6 0.0077 Zinc finger protein 22 Little or no information
NID1 459 5.1 −89.4 0.0306 nidogen 1 Promotes EMT and metastasis in ovarian, breast and lung cancer. 2841677028827399
The corrected p-value was calculated using the multiple test correction Benjamini–Hochberg. p < 0.05, fold change mean S2/S11 B4GALNT2 vs. Neo ≥ 4. The red line separates up-regulated
genes from down-regulated genes. The violet or yellow labels indicate putative tumor-promoting or tumor-restraining changes, respectively.
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A large number of modulated genes were found to be related with cancer. Through an extensive
survey of the literature, we attributed a cancer-promoting activity or a cancer-restraining activity
to the majority of the modulated genes. A violet or yellow label was assigned on the basis of the
putative tumor-promoting or tumor-restraining change (violet for up-regulation of tumor-promoting
or down-regulation of tumor-restraining and vice versa for the yellow label). Interestingly, only three
changes were putatively tumor-promoting and 12 were tumor-restraining. Some genes, which appeared
to be virtually switched off in B4GALNT2-expressing cells, are involved in the basic properties of
cancer cells, such as stemness (SOX2, ROR1), epithelial to mesenchymal transition (EMT) (NID1,
ALX1), and growth (FAM110B, PEG10, MID2). Overall, the transcriptomic changes induced by
B4GALNT2 were consistent with a general down-regulation of gene expression and an attenuation of
the neoplastic phenotype.
These data are consistent with a driving role of B4GALNT2 or its cognate Sda antigen in the
regulation of several crucial genes in LS174T cells. If this driving role of B4GALNT2 on gene expression
was also exerted in CRC tissues, a consistent regulation of these genes in TCGA patients could be
observed. Thus, we asked whether those genes that we found to be up-regulated in LS174T S2 and S11
cells were also up-regulated in patients showing high B4GALNT2 levels in cancer tissues and vice
versa for genes displaying down-regulation in S2/S11 cells. To this aim, we considered the same cohorts
of patients shown in Figure 2G, comprising 15% of non-expressers and 15% of high expressers. For the
25 genes showing modulation by B4GALNT2 reported in Table 3, we determined the mean level of
expression in the non-expressers and in the high-expressers cohorts, respectively (Table 4), from TCGA.
The “consistency” column indicates whether the observed difference between non-expressers and
high-expressers was consistent with the hypothesized role of B4GALNT2 in regulating gene expression.
Out of the 25 genes, one was not expressed and 13 showed a difference consistent with the supposed
role of B4GALNT2; for six genes, the change was statistically significant.
3.5. B4GALNT2 Expression Regulates the Transcriptional Response to 3D Culture
Owing to the markedly reduced ability to adapt to non-adherent growth displayed by
B4GALNT2-expressing cells, we asked which genes were modulated by 3D culture in LS174T cells and
which genes displayed a differential response to 3D culture conditions in B4GALNT2-expressing cells
S2/S11. Many genes were modulated by 3D culture conditions, regardless of B4GALNT2 expression
(Figure 5B). Among these, 106 displayed a fold change ≥ 4 (Table S2). Several strongly modulated genes
were involved in energy metabolism, including glycolysis (PFKFB4, ALDOC, PGM1, PGK1), and several
were part of the hypoxia response (CA9, EGLN3, EGR1). Some of these genes displayed extremely high
expression levels and were all up-regulated (PGK1, LCN15, FABP1, ALDOC, PGM1, CA9). Among the
genes involved in transcriptional regulation, the high level of expression of transcription factors FOS
and FOSB and of the transcriptional regulator EGR1 in 2D culture and their dramatic down-regulation
in 3D culture is noteworthy. On the other hand, among the genes involved in cell signaling, the gene
KIT encoding a crucial tyrosine kinase receptor displayed a high level of up-regulation in 3D culture.
Genes involved in cytoskeleton organization exhibited a general down-regulation, while those involved
in detoxification displayed up-regulation. Finally, the strong up-regulation of the genes PIGZ, involved
in the biosynthesis of the glycosylphosphatidylinositol (GPI)-anchor, and NDRG1, involved in stress
response is of note.
All the above-mentioned genes displayed 3D culture modulation regardless of B4GALNT2
expression. A search for genes differentially modulated by 3D culture depending on the expression or
non-expression of B4GALNT2 yielded a list of 31 genes, 13 of which showed up-regulation in response
to 3D culture only in S2/S11 cells, while the remaining 18 showed down-regulation in response to
3D culture only in S2/S11 cells (Table 5). The most remarkable change is the concomitant strong
down-regulation of five genes (KIZ, CEP120, DNAH6, SGOL2, STARD13) controlling cytoskeletal
organization in mitosis and motility. This finding could provide a clue to explain the reduced ability of
the B4GALNT2-expressing cells to adapt to non-adherent conditions of growth. Among the genes
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involved in cell signaling, it is important to highlight the concomitant down-regulation of three
genes encoding taste receptors, which, besides tasting bitterness, can play a tumor-suppressive role.
3D culture appears to increase the propensity to apoptosis in B4GALNT2-expressing cells by modulating
at least three genes: TNFAIP8L2, MYOD1, and PPM1K. Among the genes involved in transcriptional
regulation, the marked down-regulation of PHF20L1, which stabilizes SOX2 post-translationally [21],
must be noted, and is consistent with reduced stemness. Of the three genes related to immunity
and inflammation, CTLA4 is a well-known inhibitory receptor of T lymphocytes and is surprisingly
expressed by this CRC cell line. IL1A is an inflammatory cytokine, while TDO2 is involved in a pathway
potentially suppressing anti-tumor immune responses.
Afterward, we investigated whether the TCGA cohorts of non- or high B4GALNT2 expressers
displayed parallel modulation of the same genes, focusing on genes belonging to the major functional
classes (top five classes of Table 5). Table 6 shows that genes belonging to the groups “Cytoskeleton
and mitosis” and “Transcription regulation” in Table 5 displayed significant consistent modulation
in TCGA data, but genes TNFAIP8L2, involved in apoptosis, and IL1A involved in inflammation
and immunity, were also consistently modulated. Altogether, these data point to some mechanisms
through which B4GALNT2 expression reduces the ability to grow in conditions of poor adherence.
Table 4. Gene expression comparison between TCGA cohort (Non- and High B4GALNT2 expressers
and microarray analyisis of LS174T cells (S2/S11 comparison with Neo).
Gene Name
Non-B4GALNT2 Expressers High B4GALNT2 Expressers
Consistency p-Value
Mean ± SD Mean ± SD
Genes Down
Up-Regulated in
LS174T S2/S11
CD200 171 ± 144 250 ± 236 Yes ≤0.01
NGFRAP1 850 ± 641 843 ± 5655 Yes N.S.
SKAP1 220 ± 176 205 ± 192 No
SLC4A1 Not expressed Not expressed
Genes
Down-Regulated
in LS174T
S2/S11
FAM110B 37 ± 33 35 ± 42 Yes N.S.
ALX1 3 ± 13 4 ± 8 No
F5 325 ± 968 180 ± 627 Yes N.S.
INMT 132 ± 153 118 ± 120 Yes N.S.
MYH3 41 ± 125 16 ± 16 Yes ≤0.05
MBOAT2 498 ± 282 660 ± 405 No
ROR1 27 ± 39 25 ± 31 No
RAI14 765 ± 420 661 ± 586 Yes N.S.
FMO3 86 ± 620 26 ± 25 Yes N.S.
PEG10 136 ± 401 245 ± 685 No
NINL 168 ± 203 119 ± 123 Yes ≤0.05
ARMC4 4 ± 13 6 ± 8 No
MID2 146 ± 122 150 ± 104 No
SOX2 107 ± 281 32 ± 117 Yes ≤0.01
LGALS2 77 ± 141 128 ± 210 No
NPTX1 39 ± 95 15 ± 29 Yes ≤0.01
GALC 644 ± 525 663 ± 503 No
STARD3NL 697 ± 255 646 ± 253 Yes ≤0.1
ZNF22 625 ± 239 638 ± 267 No
NID1 1558 ± 993 1544 ± 1496 Yes N.S.
The cohorts of non-expressers (Mean ± SD = 0 ± 0) and of high-expressers (Mean ± SD = 367 ± 69) represent the
15% lower and higher percentiles of the TCGA cohort. The column “Consistency” indicates whether the difference
in gene expression of non- or high B4GALNT2 expressers was consistent with that observed by microarray analysis
of our LS174T model. Genes showing statistically significant consistent difference are indicated in bold (p ≤ 0.05
Student’s t test for independent samples). N.S. = non-significant.
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Table 5. Genes highly modulated by 3D only in B4GALNT2-expressing LS174T cells (clones S2/S11).
Gene
Symbol
Expression
Neo
Expression
S2/S11 Fold Change
3D/2D Neo
Fold Change
3D/2D S2/S11
Corrected
p-Value Gene Name Role
Broad
Functional
Category2D 3D 2D 3D
KIZ 16.2 13.4 19.0 3.8 −1.2 −4.9 0.0086 Kizuna centrosomal protein Centrosomal protein necessary to endure the forcesconverging on the centrosomes during spindle formation.
Cytoskeleton
and mitosis
CEP120 7.3 7.5 15.8 3.1 1.0 −5.2 0.0086 Centrosomal protein 120kDa Functions in the microtubule-dependent coupling of thenucleus and the centrosome.
DNAH6 6.3 5.3 13.1 2.3 −1.2 −5.7 0.0163 Dynein, axonemal, heavy chain 6 Member of the dynein family, which are constituents of themicrotubule-associated motor protein complex.
SGOL2 8.6 7.7 18.4 2.2 −1.1 −8.3 0.0086 Shugoshin-like 2 (S. pombe) Targets PPP2CA to centromeres, leading to cohesindephosphorylation.
STARD13 13.5 16.3 19.8 4.2 1.2 −4.7 0.0156 StAR-related lipid transfer (START)domain containing 13
Involved in regulation of cytoskeletal reorganization, cell
proliferation and motility.
UPK1A 4.0 3.7 1.9 12.0 −1.1 6.3 0.0086 Uroplakin 1A
Member of the tetraspanin family, mediates signaling.
Decreased expression is associated with CRC progression
and poor prognosis. (PMID: 25197375)
Cell signalingOR52R1 11.2 10.3 3.3 15.5 −1.1 4.8 0.0131
Olfactory receptor, family 52,
subfamily R, member 1
(gene/pseudogene)
Olfactory receptors are G-protein-coupled receptors
involved in perception of smell and other functions.
TAS2R45 42.6 35.9 68.8 17.2 −1.2 −4.0 0.0247 Taste receptor, type 2, member 45 Taste receptors play a role in the perception of bitterness
and in sensing the chemical composition of the
gastrointestinal content. Some taste receptors inhibit cancer
growth and stemness. (PMID: 28467517)
TAS2R19 41.9 31.8 70.3 17.1 −1.3 −4.1 0.0116 Taste receptor, type 2, member 19
TAS2R30 254.5 215.3 402.3 81.8 −1.2 −4.9 0.0168 Taste receptor, type 2, member 30
TNFAIP8L2 4.7 6.0 2.0 14.5 1.3 7.3 0.0319 Tumor necrosis factor,alpha-induced protein 8-like 2 Promotes Fas-induced apoptosis. (PMID: 28186089)
Apoptosis
MYOD1 3.4 5.7 2.3 10.4 1.7 4.4 0.0239 Myogenic differentiation 1 Mediates apoptosis through caspase 3. (PMID: 28131747)
PPM1K 16.3 11.7 25.7 4.0 −1.4 −6.5 0.0086 Protein phosphatase, Mg2+/Mn2+dependent, 1K
Regulates the mitochondrial permeability transition pore
and is essential for cellular survival.
SDPR
(CAVIN2) 4.3 1.8 18.3 2.3 −2.4 −8.1 0.0106 Serum deprivation response
Role in caveolar biogenesis and morphology. Metastasis
suppressor and activator of apoptosis. (PMID: 26739564).
PHF20L1 7.4 7.1 24.2 2.7 1.0 −8.9 0.0089 PHD finger protein 20-like 1 Predicted to be involved in regulation of transcription.Stabilizes SOX2 postranslationally. (PMID: 30089852)
Transcription
regulation
KLF12 5.2 3.9 12.3 2.2 −1.3 −5.7 0.0235 Kruppel-like factor 12
Inhibitor of the AP-2 alpha transcription factor. Inhibits
growth and anoikis resistance of ovarian cancer cells.
(PMID: 28095864)
PCF11 3.6 5.0 6.7 1.7 1.4 −4.0 0.0086 PCF11 cleavage andpolyadenylation factor subunit It is necessary for efficient Pol II transcription termination
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Table 5. Cont.
Gene
Symbol
Expression
Neo
Expression
S2/S11 Fold Change
3D/2D Neo
Fold Change
3D/2D S2/S11
Corrected
p-Value Gene Name Role
Broad
Functional
Category2D 3D 2D 3D
CTLA4 2.1 3.7 2.4 14.2 1.7 5.8 0.0136 Cytotoxic T-lymphocyte-associatedprotein 4 Inhibitor of T cell activation.
Immunity and
inflammation
IL1A 1.7 2.8 2.1 11.7 1.7 5.6 0.0259 Interleukin 1α Involved in immune responses andinflammatory processes.
TDO2 3.1 6.5 7.3 29.0 2.1 4.0 0.0086 Tryptophan 2,3-dioxygenase
In tryptophan metabolism catalyzes the first step of the
kynurenine pathway. Increased kynurenine may suppress
antitumor immune responses.
FSIP2 8.3 5.8 17.0 2.9 −1.4 −5.9 0.0365 Fibrous sheath interacting protein 2 Protein associated with the sperm fibrous sheath.
FertilizationSPACA1 5.5 6.4 4.1 18.2 1.2 4.5 0.0293 Sperm acrosome associated 1
Localizes to the acrosomal membrane of spermatozoa,
playing a role in acrosomal morphogenesis and in
sperm-egg fusion.
USP11 6.1 7.0 3.3 13.3 1.1 4.0 0.0352 Ubiquitin specific peptidase 11 Encodes a cysteine protease that cleaves ubiquitin fromubiquitin-conjugated protein substrates. Ubiquitination
ST13 6.9 12.8 2.7 11.0 1.9 4.1 0.0090
Suppression of tumorigenicity 13
(colon carcinoma) (Hsp70
interacting protein)
Mediates the association of the heat shock proteins HSP70
and HSP90. Protein folding
HIST4H4 81.2 193.8 101.6 406.8 2.4 4.0 0.0365 Histone cluster 4, H4 Component of the nucleosome. Chromatinstructure
TRAPPC2 10.3 7.1 8.4 1.9 −1.5 −4.4 0.0086 Trafficking protein particlecomplex 2
May play a role in vesicular transport from endoplasmic
reticulum to Golgi
Intracellular
transport
C8orf74 6.3 5.3 10.1 2.3 −1.2 −4.4 0.0135 Chromosome 8 open readingframe 74
Little or no information
NAALADL2 15.5 10.4 17.9 4.1 −1.5 −4.3 0.0196 N-acetylated alpha-linked acidicdipeptidase-like 2
SAMD12 21.1 17.1 25.8 6.3 −1.2 −4.1 0.0323 Sterile alpha motif domaincontaining 12
FRG2 40.8 49.1 40.2 173.8 1.2 4.3 0.0138 FSHD region gene 2
FRG2C 3.5 8.4 7.2 35.0 2.4 4.9 0.0124 FSHD region gene 2 family,member C
Corrected p-value was calculated using the multiple test correction Benjamini–Hochberg (p < 0.05, fold change B4GALNT2 3D vs. B4GALNT2 2D). Information on the gene role were
obtained from Genecards [22] and from PubMed.
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Table 6. Gene expression comparison between TCGA cohort (Non- and High B4GALNT2 expressers
and microarray analyisis of LS174T cells (modulated by 3D only in S2/S11).
Gene Name
Non-B4GALNT2
Expressers
High B4GALNT2
Expressers Consistency p-Value
Mean ± SD Mean ± SD
Cytoskeleton
and mitosis
KIZ (PLK1S1) 346 ± 302 250 ± 154 Yes ≤0.01
CEP120 404 ± 116 340 ± 135 Yes ≤0.01
DNAH6 33 ± 28 27 ± 15 Yes ≤0.05
SGOL2 316 ± 124 273 ± 138 Yes ≤0.01
STARD13 529 ± 271 355 ± 211 Yes ≤0.01
Cell signaling UPK1A 16 ± 112 5 ± 21 Yes N.S.
Apoptosis
TNFAIP8L2 46 ± 38 58 ± 42 Yes ≤0.05
PPM1K 97 ± 133 10 ± 45 No
SDPR 186 ± 271 153 ± 162 Yes N.S
Transcription
regulation
PHF20L1 941 ± 296 794 ± 349 Yes ≤0.01
KLF12 239 ± 199 179 ± 128 Yes ≤0.01
PCF11 1025 ± 302 856 ± 227 Yes ≤0.01
Immunity and
inflammation
CTLA4 47 ± 85 42 ± 34 No
IL1A 34 ± 86 69 ± 215 Yes ≤0.05
TDO2 232 ± 885 115 ± 156 No
The mean level of expression in TCGA database of genes selectively modulated by 3D growth only in S2/S11 cells
(Table 5) was compared in the cohorts of non-B4GALNT2 expressers and of high B4GALNT2 expressers as in
Table 4. The column “Consistency” indicates whether the difference observed in the cohorts was consistent with
that reported in Table 5. Genes showing statistically significant consistent difference are indicated in bold (p ≤ 0.05
Student’s t test for independent samples). N.S. = non-significant. A few genes present in Table 5 are not present in
this Table because they were not present in TCGA or not expressed.
4. Discussion
In this study, we show for the first time that in a large cohort of colon cancer samples, the mRNA
of B4GALNT2 is dramatically down-regulated compared with normal tissue, consistent with previous
observations of a reduced B4GALNT2 enzymatic activity in CRC tissues [8,10]. In addition, we observed
that all patients surviving beyond three years displayed a high level of B4GALNT2 mRNA, indicating
a strong relationship between high B4GALNT2 and lower malignancy. In other TCGA cohorts,
the association of high B4GALNT2 with survival was not observed, suggesting that it is restricted
to CRC. To understand whether high B4GALNT2 and lower malignancy were causally related,
we analyzed the phenotype of LS174T cells permanently modified to express B4GALNT2 cDNA.
This cell line was chosen because it is devoid of B4GALNT2 activity and of cognate Sda antigen (like the
vast majority of colon cancer cell lines) and is one of the few CRC cell lines expressing the sLex antigen.
In our system, B4GALNT2 expression resulted in a partial replacement of the sLex epitope with Sda.
While little or no effect was observed on the ability to heal a scratch wound or to form clones in standard
conditions of growth, B4GALNT2 expression resulted in a dramatic inhibition of the ability to grow in
poor or no adherence, pointing to a specific effect of B4GALNT2 in regulating this property. The ability
to survive and proliferate without the intracellular signals generated by the mechanosensors [23] is
intimately associated with resistance to apoptosis and stemness. Consistently, we observed that in
B4GALNT2-expressing cells, the percentage of stem cells was reduced. For this reason, we investigated
the effect of B4GALNT2 on the transcriptome of transfected LS174T cell variants. The ability to modulate
the transcriptome of cancer cells by a glycosyltransferase was previously documented [17,24–26].
Nevertheless, the transcriptomic changes induced by B4GALNT2 in standard conditions of growth
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were surprisingly relevant. In particular, the marked transcriptional down-regulation of protein-coding
genes in B4GALNT2-expressing cells may conceivably be related to a reduced ability to perform several
cellular functions. The fact that the vast majority of these genes displayed cancer-promoting activity in
different systems is consistent with an attenuation of the cancer phenotype in LS174T cells. Moreover,
a causative role of B4GALNT2 in the control of these genes was supported by the observation that in the
TCGA cohorts of high and low B4GALNT2 expressers, the mean level of expression of these genes was
in some cases significantly consistent with that observed in LS174T cells. Among the genes showing
significant inverse association with B4GALNT2 expression in TCGA, SOX2 is particularly relevant for
its role in CRC stemness [27]. Its dramatic down-regulation in S2/S11 clones can certainly contribute
to explaining their reduced ability to grow in non-adherent conditions and their reduced content
of stem cells. To understand which genes were modulated by non-adherent growth, we analyzed
the transcriptome of cells grown as spheroids in 3D conditions. We were particularly interested
in understanding which genes were differentially modulated by 3D growth, depending on their
B4GALNT2 expression. Growth in 3D conditions modulates a large number of genes, mainly involved
in energy metabolisms, transcription, cell signaling, and detoxifying activity. Several genes belong to
the hypoxia response, which is not surprising, considering the hypoxic conditions present at the center
of the spheroids [28]. However, the genes responding to 3D growth only in B4GALNT2-expressing cells
appeared to impair mainly the function of microtubules in mitosis but also transcription, cell signaling,
and apoptosis, thus explaining the reduced ability of B4GALNT2-expressing cells to grow in poorly
adherent conditions. Interestingly, all the genes belonging to the groups “Cytoskeleton and mitosis”
and “Transcription regulation” displayed consistent association with B4GALNT2 level in TCGA cohort.
In addition, the gene TNFAIPL2, which promotes apoptosis, and the gene of the pro-inflammatory
cytokine, IL1A, also displayed consistent modulation in the TCGA cohort. Although IL1A plays
different and sometimes opposite roles when expressed by cells of the tumor microenvironment,
when it is expressed by CRC cells, it is immunostimulatory and induces an anti-tumor immune
response [29]. Current data support the notion that high B4GALNT2 is causally related to a better
prognosis because it can reduce stemness and capability to grow in poorly adherent conditions, and it
increases the propensity to apoptosis and stimulates anti-cancer immunity. Although our data do not
clarify whether the observed effects of B4GALNT2 expression are due to the de novo expression of the
Sda antigen or the down-regulation of sLex, they point to the potential usefulness of B4GALNT2 to
stratify patients’ risk, contributing to the design of a personalized therapy of colon cancer.
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